Currently, there are 64.56M common shares owned by the public and among those 62.21M shares have been available to trade.
The company’s stock has a 5-day price change of 25.90% and 42.38% over the past three months. BPMC shares are trading 46.51% year to date (YTD), with the 12-month market performance up to 27.07% higher. It has a 12-month low price of $73.04 and touched a high of $121.90 over the same period. BPMC has an average intraday trading volume of 991.09K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 25.89%, 37.69%, and 36.48% respectively.
Institutional ownership of Blueprint Medicines Corp (NASDAQ: BPMC) shares accounts for 106.92% of the company’s 64.56M shares outstanding.
It has a market capitalization of $8.25B and a beta (3y monthly) value of 0.84. The earnings-per-share (ttm) stands at -$2.46. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.59% over the week and 5.88% over the month.
Earnings per share for the fiscal year are expected to increase by 34.23%, and 230.03% over the next financial year.
Looking at the support for the BPMC, a number of firms have released research notes about the stock. Wedbush stated their Neutral rating for the stock in a research note on Jun-03-25, with the firm’s price target at $129. Morgan Stanley coverage for the Blueprint Medicines Corp (BPMC) stock in a research note released on March 20, 2025 offered a Equal-Weight rating with a price target of $100. Wolfe Research was of a view on March 18, 2025 that the stock is Outperform, while Jefferies gave the stock Buy rating on March 17, 2025, issuing a price target of $135. Scotiabank on their part issued Sector Outperform rating on March 07, 2025.
